TD Cowen Upgrades Maze Therapeutics (NASDAQ:MAZE) to “Strong-Buy”

Maze Therapeutics (NASDAQ:MAZE) was upgraded by TD Cowen to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports.

MAZE has been the subject of several other reports. JPMorgan Chase & Co. assumed coverage on shares of Maze Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $30.00 target price for the company. Leerink Partnrs raised Maze Therapeutics to a “strong-buy” rating in a research report on Tuesday. Guggenheim began coverage on Maze Therapeutics in a research note on Tuesday. They set a “buy” rating and a $19.00 target price for the company. Finally, Leerink Partners started coverage on Maze Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $28.00 price target on the stock. Three analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics currently has an average rating of “Buy” and an average target price of $25.67.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $11.70 on Tuesday. Maze Therapeutics has a one year low of $10.08 and a one year high of $17.00.

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.